Primary thrombocythemia is when the bone marrow is making too many platelets without a known cause. Platelets are needed for blood clotting.
Primary thrombocythemia is caused by too much growth of a type of cell that is used to make blood cells. The platelets are mostly affected, but the red blood cells and white blood cells may be involved as well. This condition slowly gets worse over time. Because these platelets do not work normally, bleeding is a common problem.
The disease is part of a group of conditions known myeloproliferative disorders. Others include:
Most of the time, this condition affects people in middle age. It is also seen in younger people, especially women under age 40.
The condition may even cause strokes in some people.
Most of the time, this condition is found through blood tests done for other conditions before symptoms appear.
Your health care provider will do a physical exam to look for an enlarged spleen or liver. You may also have abnormal blood flow in the toes or feet that causes skin damage in these areas.
Other tests may include:
The doctors can do a procedure to remove platelets directly from the blood if you have life-threatening complications.
Long-term, you will need to take medicines to decrease the platelet count and avoid complications. The most common of these medicines are hydroxyurea, interferon-alpha, or anagrelide. In some people with a JAK2 mutation, specific inhibitors of the JAK2 protein may be used.
In people who are at a high risk for clotting, aspirin at a low dose (81 to 100 mg per day) decreases clotting episodes. People who may benefit from this treatment include older persons and people with very high platelet levels or who have had past clotting episodes.
Many people do not need any treatment. However, the health care provider should monitor your condition.
The outcome varies. Most people go for long periods without complications and have a normal lifespan. Complications from bleeding and blood clots can cause serious problems in a small number of people.
Rarely, the disease will change into acute leukemia or myelofibrosis.
Call your health care provider if:
Essential thrombocythemia; Essential thrombocytosis
Hoffman R, Kremyanskaya M, Najfeld V, et al. Essential thrombocythemia. In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, eds. Hematology: Basic Principles and Practice. 6th ed. Philadelphia, PA: Elsevier Saunders; 2012:chap 68.
Tefferi A. Polycythemias, Essential thrombocytoemia, and primary myelobirosis. In: Goldman L, Schafer AI, eds. Goldman's Cecil Medicine. 24th ed. Philadelphia, PA: Elsevier Saunders; 2011:chap 169.
Updated by: Yi-Bin Chen, MD, Leukemia/Bone Marrow Transplant Program, Massachusetts General Hospital, Boston, MA. Also reviewed by A.D.A.M. Health Solutions, Ebix, Inc., Editorial Team: David Zieve, MD, MHA, Bethanne Black, Stephanie Slon, and Nissi Wang.
The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed physician should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. Copyright 1997-2014, A.D.A.M., Inc. Duplication for commercial use must be authorized in writing by ADAM Health Solutions.